Bristol's Early Alzheimer's Research Takes A Different Tack

Like many other drug makers, Bristol-Myers Squibb has its eye on the potentially lucrative market for a disease-modifying Alzheimer's disease therapy. During an investor meeting March 4, management highlighted the early- to mid-stage Alzheimer's pipeline and outlined one novel approach: targeting the disease earlier before Alzheimer's symptoms develop